Key clinical point: Preliminary evidence indicated feasibility of LY2780301, a dual inhibitor of p70 ribosomal protein S6 kinase and protein kinase B (AKT) and paclitaxel combination in patients with hormone-resistant2 (HER2)-negative advanced breast cancer (BC).

Major finding: The recommended phase 2 dose was LY2780301 500 mg once daily + weekly paclitaxel 80 mg/m². The 6-month objective response rate for phase 2 was 63.9% (90% CI, 48.8-76.8) in the overall population and 55% (90% CI, 35.0-73.7) in phosphatidylinositol-3-kinase/AKT positive patients. The common drug-related adverse events were neuropathy, asthenia, ungual toxicity and pneumonitis.

Study details: Findings are from a prospective, multi-centred, phase 1b/2 TAKTIC trial including 48 patients with HER2-negative advanced BC with (phase 1B; n=12) or without (phase 2; n=36) previous cytotoxic treatment for advanced disease who were administered oral LY2780301 + intravenous paclitaxel.

Disclosures: This study was funded by the French National Cancer Institute, the Caritative Foundation and the Ligue Nationale Contre le Cancer. Three authors declared serving as advisory board member and/or receiving research grants and non-financial support from various pharmaceutical companies.

Source: Vicier C et al. Eur J Cancer. 2021 Nov 12. doi: 10.1016/j.ejca.2021.09.040.

Key clinical point: Preliminary evidence indicated feasibility of LY2780301, a dual inhibitor of p70 ribosomal protein S6 kinase and protein kinase B (AKT) and paclitaxel combination in patients with hormone-resistant2 (HER2)-negative advanced breast cancer (BC).

Major finding: The recommended phase 2 dose was LY2780301 500 mg once daily + weekly paclitaxel 80 mg/m². The 6-month objective response rate for phase 2 was 63.9% (90% CI, 48.8-76.8) in the overall population and 55% (90% CI, 35.0-73.7) in phosphatidylinositol-3-kinase/AKT positive patients. The common drug-related adverse events were neuropathy, asthenia, ungual toxicity and pneumonitis.

Study details: Findings are from a prospective, multi-centred, phase 1b/2 TAKTIC trial including 48 patients with HER2-negative advanced BC with (phase 1B; n=12) or without (phase 2; n=36) previous cytotoxic treatment for advanced disease who were administered oral LY2780301 + intravenous paclitaxel.

Disclosures: This study was funded by the French National Cancer Institute, the Caritative Foundation and the Ligue Nationale Contre le Cancer. Three authors declared serving as advisory board member and/or receiving research grants and non-financial support from various pharmaceutical companies.

Source: Vicier C et al. Eur J Cancer. 2021 Nov 12. doi: 10.1016/j.ejca.2021.09.040.

Key clinical point: Preliminary evidence indicated feasibility of LY2780301, a dual inhibitor of p70 ribosomal protein S6 kinase and protein kinase B (AKT) and paclitaxel combination in patients with hormone-resistant2 (HER2)-negative advanced breast cancer (BC).

Major finding: The recommended phase 2 dose was LY2780301 500 mg once daily + weekly paclitaxel 80 mg/m². The 6-month objective response rate for phase 2 was 63.9% (90% CI, 48.8-76.8) in the overall population and 55% (90% CI, 35.0-73.7) in phosphatidylinositol-3-kinase/AKT positive patients. The common drug-related adverse events were neuropathy, asthenia, ungual toxicity and pneumonitis.

Study details: Findings are from a prospective, multi-centred, phase 1b/2 TAKTIC trial including 48 patients with HER2-negative advanced BC with (phase 1B; n=12) or without (phase 2; n=36) previous cytotoxic treatment for advanced disease who were administered oral LY2780301 + intravenous paclitaxel.

Disclosures: This study was funded by the French National Cancer Institute, the Caritative Foundation and the Ligue Nationale Contre le Cancer. Three authors declared serving as advisory board member and/or receiving research grants and non-financial support from various pharmaceutical companies.

Source: Vicier C et al. Eur J Cancer. 2021 Nov 12. doi: 10.1016/j.ejca.2021.09.040.

Key clinical point: Dalpiciclib plus fulvestrant prolonged progression-free survival (PFS) compared with placebo+fulvestrant in patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer who progressed during or after endocrine therapy.

Major finding: Patients receiving dalpiciclib+fulvestrant showed significantly prolonged investigator-assessed progression-free survival than those who received placebo+fulvestrant (median, 15.7 months vs 7.2 months; hazard ratio, 0.42; P < .0001). Serious adverse events were reported by 5.8% vs 6.7% of patients recieving dalpiciclib+fulvestrant vs placebo+fulvestrant.

Study details: Findings are interim results from phase 3 DAWNA-1 trial, including 361 patients with HR-positive, HER2-negative locally advanced breast cancer who progressed on endocrine therapy and were randomly assigned to dalpiciclib+fulvestrant or placebo+fulvestrant.

Disclosures: This study was funded by Jiangsu Hengrui Pharmaceuticals. The authors reported receiving research grants, advisory fees from Hengrui and other sources. Four authors declared being employees of Hengrui.

Source: Xu B et al. Nat Med. 2021 Nov 4. doi: 10.1038/s41591-021-01562-9.

Key clinical point: Dalpiciclib plus fulvestrant prolonged progression-free survival (PFS) compared with placebo+fulvestrant in patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer who progressed during or after endocrine therapy.

Major finding: Patients receiving dalpiciclib+fulvestrant showed significantly prolonged investigator-assessed progression-free survival than those who received placebo+fulvestrant (median, 15.7 months vs 7.2 months; hazard ratio, 0.42; P < .0001). Serious adverse events were reported by 5.8% vs 6.7% of patients recieving dalpiciclib+fulvestrant vs placebo+fulvestrant.

Study details: Findings are interim results from phase 3 DAWNA-1 trial, including 361 patients with HR-positive, HER2-negative locally advanced breast cancer who progressed on endocrine therapy and were randomly assigned to dalpiciclib+fulvestrant or placebo+fulvestrant.

Disclosures: This study was funded by Jiangsu Hengrui Pharmaceuticals. The authors reported receiving research grants, advisory fees from Hengrui and other sources. Four authors declared being employees of Hengrui.

Source: Xu B et al. Nat Med. 2021 Nov 4. doi: 10.1038/s41591-021-01562-9.

Key clinical point: Dalpiciclib plus fulvestrant prolonged progression-free survival (PFS) compared with placebo+fulvestrant in patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer who progressed during or after endocrine therapy.

Major finding: Patients receiving dalpiciclib+fulvestrant showed significantly prolonged investigator-assessed progression-free survival than those who received placebo+fulvestrant (median, 15.7 months vs 7.2 months; hazard ratio, 0.42; P < .0001). Serious adverse events were reported by 5.8% vs 6.7% of patients recieving dalpiciclib+fulvestrant vs placebo+fulvestrant.

Study details: Findings are interim results from phase 3 DAWNA-1 trial, including 361 patients with HR-positive, HER2-negative locally advanced breast cancer who progressed on endocrine therapy and were randomly assigned to dalpiciclib+fulvestrant or placebo+fulvestrant.

Disclosures: This study was funded by Jiangsu Hengrui Pharmaceuticals. The authors reported receiving research grants, advisory fees from Hengrui and other sources. Four authors declared being employees of Hengrui.

Source: Xu B et al. Nat Med. 2021 Nov 4. doi: 10.1038/s41591-021-01562-9.

Key clinical point: Final 12-year results from the PROMISE-GIM6 study reassures safety of concurrent administration of gonadotropin-releasing hormone agonist (GnRHa), triptorelin during chemotherapy in premenopausal women with early breast cancer (BC).

Major finding: The 12-year disease-free survival (65.7 % vs 69.2%; hazard ratio [HR], 1.16; P = .50), overall survival (81.2 % vs 81.3%; HR, 1.17; P = .58), and posttreatment pregnancy (9 vs 4 patients; HR, 2.14; P = .20) were not significantly different in GnRHa+chemotherapy vs chemotherapy-only groups.

Study details: PROMISE-GIM6, a phase 3 superiority trial included 281 premenopausal women with hormone receptor-positive or -negative early BC who were randomly assigned to receive GnRHa+chemotherapy or chemotherapy alone.

Disclosures: This study was funded by IRCCS Ospedale Policlinico San Martino and Associazione Italiana per la Ricerca sul Cancro and the Italian Ministry of Health. Some of the authors declared serving as a consultant and/or receiving speaker honoraria and travel accommodation from various pharmaceutical companies.

Source: Lambertini M et al. J Natl Cancer Inst. 2021 Nov 25. doi: 10.1093/jnci/djab213.

Key clinical point: Final 12-year results from the PROMISE-GIM6 study reassures safety of concurrent administration of gonadotropin-releasing hormone agonist (GnRHa), triptorelin during chemotherapy in premenopausal women with early breast cancer (BC).

Major finding: The 12-year disease-free survival (65.7 % vs 69.2%; hazard ratio [HR], 1.16; P = .50), overall survival (81.2 % vs 81.3%; HR, 1.17; P = .58), and posttreatment pregnancy (9 vs 4 patients; HR, 2.14; P = .20) were not significantly different in GnRHa+chemotherapy vs chemotherapy-only groups.

Study details: PROMISE-GIM6, a phase 3 superiority trial included 281 premenopausal women with hormone receptor-positive or -negative early BC who were randomly assigned to receive GnRHa+chemotherapy or chemotherapy alone.

Disclosures: This study was funded by IRCCS Ospedale Policlinico San Martino and Associazione Italiana per la Ricerca sul Cancro and the Italian Ministry of Health. Some of the authors declared serving as a consultant and/or receiving speaker honoraria and travel accommodation from various pharmaceutical companies.

Source: Lambertini M et al. J Natl Cancer Inst. 2021 Nov 25. doi: 10.1093/jnci/djab213.

Key clinical point: Final 12-year results from the PROMISE-GIM6 study reassures safety of concurrent administration of gonadotropin-releasing hormone agonist (GnRHa), triptorelin during chemotherapy in premenopausal women with early breast cancer (BC).

Major finding: The 12-year disease-free survival (65.7 % vs 69.2%; hazard ratio [HR], 1.16; P = .50), overall survival (81.2 % vs 81.3%; HR, 1.17; P = .58), and posttreatment pregnancy (9 vs 4 patients; HR, 2.14; P = .20) were not significantly different in GnRHa+chemotherapy vs chemotherapy-only groups.

Study details: PROMISE-GIM6, a phase 3 superiority trial included 281 premenopausal women with hormone receptor-positive or -negative early BC who were randomly assigned to receive GnRHa+chemotherapy or chemotherapy alone.

Disclosures: This study was funded by IRCCS Ospedale Policlinico San Martino and Associazione Italiana per la Ricerca sul Cancro and the Italian Ministry of Health. Some of the authors declared serving as a consultant and/or receiving speaker honoraria and travel accommodation from various pharmaceutical companies.

Source: Lambertini M et al. J Natl Cancer Inst. 2021 Nov 25. doi: 10.1093/jnci/djab213.

Key clinical point: Chemoendocrine therapy vs endocrine-only therapy conferred longer invasive disease-free survival (iDFS) in premenopausal women with node-positive (node+) breast cancer (BC) and a recurrence score (RS) of ≤25 on a 21-gene assay.

Major finding: The 5-year iDFS was 93.9% in chemoendocrine group vs 89% in endocrine-only group with a significant chemotherapy benefit in premenopausal women (hazard ratio, 0.60; P = .002).

Study details: Findings are from RxPONDER, a prospective, ongoing phase 3 study, including 5,083 women with hormone receptor-positive/human epidermal growth factor receptor 2-negative BC, positive axillary lymph nodes, and RS of ≤25 who were randomly assigned to endocrine-only therapy or chemoendocrine therapy.

Disclosures: This study was supported by the National Cancer Institute, Susan G. Komen for the Cure Research Program, Hope Foundation for Cancer Research, Breast Cancer Research Foundation, and Genomic Health. The authors declared serving as a consultant, advisory board member, investigator and/or receiving grants and travel allowance from several sources.

Source: Kalinsky K et al. New Eng J Med. 2021 Dec 1. doi: 10.1056/NEJMoa2108873.

Key clinical point: Chemoendocrine therapy vs endocrine-only therapy conferred longer invasive disease-free survival (iDFS) in premenopausal women with node-positive (node+) breast cancer (BC) and a recurrence score (RS) of ≤25 on a 21-gene assay.

Major finding: The 5-year iDFS was 93.9% in chemoendocrine group vs 89% in endocrine-only group with a significant chemotherapy benefit in premenopausal women (hazard ratio, 0.60; P = .002).

Study details: Findings are from RxPONDER, a prospective, ongoing phase 3 study, including 5,083 women with hormone receptor-positive/human epidermal growth factor receptor 2-negative BC, positive axillary lymph nodes, and RS of ≤25 who were randomly assigned to endocrine-only therapy or chemoendocrine therapy.

Disclosures: This study was supported by the National Cancer Institute, Susan G. Komen for the Cure Research Program, Hope Foundation for Cancer Research, Breast Cancer Research Foundation, and Genomic Health. The authors declared serving as a consultant, advisory board member, investigator and/or receiving grants and travel allowance from several sources.

Source: Kalinsky K et al. New Eng J Med. 2021 Dec 1. doi: 10.1056/NEJMoa2108873.

Key clinical point: Chemoendocrine therapy vs endocrine-only therapy conferred longer invasive disease-free survival (iDFS) in premenopausal women with node-positive (node+) breast cancer (BC) and a recurrence score (RS) of ≤25 on a 21-gene assay.

Major finding: The 5-year iDFS was 93.9% in chemoendocrine group vs 89% in endocrine-only group with a significant chemotherapy benefit in premenopausal women (hazard ratio, 0.60; P = .002).

Study details: Findings are from RxPONDER, a prospective, ongoing phase 3 study, including 5,083 women with hormone receptor-positive/human epidermal growth factor receptor 2-negative BC, positive axillary lymph nodes, and RS of ≤25 who were randomly assigned to endocrine-only therapy or chemoendocrine therapy.

Disclosures: This study was supported by the National Cancer Institute, Susan G. Komen for the Cure Research Program, Hope Foundation for Cancer Research, Breast Cancer Research Foundation, and Genomic Health. The authors declared serving as a consultant, advisory board member, investigator and/or receiving grants and travel allowance from several sources.

Source: Kalinsky K et al. New Eng J Med. 2021 Dec 1. doi: 10.1056/NEJMoa2108873.

Key clinical point: A higher preoperative multiparametric magnetic resonance imaging (mpMRI) Prostate Imaging Reporting and Data System (PI‐RADS) score is associated with upstaging on surgical pathology in patients with prostate cancer.

Major finding: PI-RADS score was greater than 3 in 87% of patients. Upstaging was reported in 47% of patients. PI-RADS was an independent risk predictor for upstaging (adjusted odds ratio, 2.034; P < .001).

Study details: A retrospective study of 294 patients with prostate cancer who underwent a prostate mpMRI and radical prostatectomy between 2016 and 2020.

Disclosures: No funding source was identified for this work. The authors declared no conflict of interests.

Source: Pockros B et al. Prostate. 2021 Dec 8. doi: 10.1002/pros.24280.

Key clinical point: A higher preoperative multiparametric magnetic resonance imaging (mpMRI) Prostate Imaging Reporting and Data System (PI‐RADS) score is associated with upstaging on surgical pathology in patients with prostate cancer.

Major finding: PI-RADS score was greater than 3 in 87% of patients. Upstaging was reported in 47% of patients. PI-RADS was an independent risk predictor for upstaging (adjusted odds ratio, 2.034; P < .001).

Study details: A retrospective study of 294 patients with prostate cancer who underwent a prostate mpMRI and radical prostatectomy between 2016 and 2020.

Disclosures: No funding source was identified for this work. The authors declared no conflict of interests.

Source: Pockros B et al. Prostate. 2021 Dec 8. doi: 10.1002/pros.24280.

Key clinical point: A higher preoperative multiparametric magnetic resonance imaging (mpMRI) Prostate Imaging Reporting and Data System (PI‐RADS) score is associated with upstaging on surgical pathology in patients with prostate cancer.

Major finding: PI-RADS score was greater than 3 in 87% of patients. Upstaging was reported in 47% of patients. PI-RADS was an independent risk predictor for upstaging (adjusted odds ratio, 2.034; P < .001).

Study details: A retrospective study of 294 patients with prostate cancer who underwent a prostate mpMRI and radical prostatectomy between 2016 and 2020.

Disclosures: No funding source was identified for this work. The authors declared no conflict of interests.

Source: Pockros B et al. Prostate. 2021 Dec 8. doi: 10.1002/pros.24280.

Key clinical point: Cumulative androgen deprivation therapy (ADT) is associated with a significant risk for dementia in older men with prostate cancer.

Major finding: At a median follow-up of 7 years, 2.3% of patients were diagnosed with dementia. Cumulative ADT use showed a significant association with dementia (hazard ratio [HR], 2.02; P < .01). No significant association was seen between primary treatment type and onset of dementia in the patients who did not receive ADT (HR, 1.4; P = .14).

Study details: A retrospective study of 13,570 patients aged ≥50 years from the CaPSURE registry diagnosed with prostate cancer between 1995 and 2017.

Disclosures: This study was supported by the UCSF Goldberg-Benioff Program in Translational Cancer Biology. The authors reported no competing interests.

Source: Lonergan PE et al. J Urol. 2021 Dec 2. doi: 10.1097/JU.0000000000002335.

Key clinical point: Cumulative androgen deprivation therapy (ADT) is associated with a significant risk for dementia in older men with prostate cancer.

Major finding: At a median follow-up of 7 years, 2.3% of patients were diagnosed with dementia. Cumulative ADT use showed a significant association with dementia (hazard ratio [HR], 2.02; P < .01). No significant association was seen between primary treatment type and onset of dementia in the patients who did not receive ADT (HR, 1.4; P = .14).

Study details: A retrospective study of 13,570 patients aged ≥50 years from the CaPSURE registry diagnosed with prostate cancer between 1995 and 2017.

Disclosures: This study was supported by the UCSF Goldberg-Benioff Program in Translational Cancer Biology. The authors reported no competing interests.

Source: Lonergan PE et al. J Urol. 2021 Dec 2. doi: 10.1097/JU.0000000000002335.

Key clinical point: Cumulative androgen deprivation therapy (ADT) is associated with a significant risk for dementia in older men with prostate cancer.

Major finding: At a median follow-up of 7 years, 2.3% of patients were diagnosed with dementia. Cumulative ADT use showed a significant association with dementia (hazard ratio [HR], 2.02; P < .01). No significant association was seen between primary treatment type and onset of dementia in the patients who did not receive ADT (HR, 1.4; P = .14).

Study details: A retrospective study of 13,570 patients aged ≥50 years from the CaPSURE registry diagnosed with prostate cancer between 1995 and 2017.

Disclosures: This study was supported by the UCSF Goldberg-Benioff Program in Translational Cancer Biology. The authors reported no competing interests.

Source: Lonergan PE et al. J Urol. 2021 Dec 2. doi: 10.1097/JU.0000000000002335.

Key clinical point: More than 9% of men with prostate cancer undergoing radical prostatectomy report a bad urinary incontinence score. Only approximately 9% of these men receive subsequent incontinence surgery.

Major finding: About 5,165 men completed a posttreatment survey after a median time of 18.6 months. A “bad” urinary incontinence score was reported by 9.3% of patients, and 4% also reported having had a big problem with their urinary function. Only 9.1% of patients with "bad" urinary incontinence scores underwent incontinence surgery within 6 months.

Study details: A retrospective study of 11,290 patients with prostate cancer who underwent radical prostatectomy between April 2014 and January 2016.

Disclosures: This work was supported by National Institute of Health Research, Medical Research Council, University College London Hospitals/University College London Comprehensive Biomedical Research Centre, and others. The authors received honoraria, advisory fees, travel expenses, and/or being employed outside this work.

Source: Parry MG et al. BJU Int. 2021 Nov 30. doi: 10.1111/bju.15663.

Key clinical point: More than 9% of men with prostate cancer undergoing radical prostatectomy report a bad urinary incontinence score. Only approximately 9% of these men receive subsequent incontinence surgery.

Major finding: About 5,165 men completed a posttreatment survey after a median time of 18.6 months. A “bad” urinary incontinence score was reported by 9.3% of patients, and 4% also reported having had a big problem with their urinary function. Only 9.1% of patients with "bad" urinary incontinence scores underwent incontinence surgery within 6 months.

Study details: A retrospective study of 11,290 patients with prostate cancer who underwent radical prostatectomy between April 2014 and January 2016.

Disclosures: This work was supported by National Institute of Health Research, Medical Research Council, University College London Hospitals/University College London Comprehensive Biomedical Research Centre, and others. The authors received honoraria, advisory fees, travel expenses, and/or being employed outside this work.

Source: Parry MG et al. BJU Int. 2021 Nov 30. doi: 10.1111/bju.15663.

Key clinical point: More than 9% of men with prostate cancer undergoing radical prostatectomy report a bad urinary incontinence score. Only approximately 9% of these men receive subsequent incontinence surgery.

Major finding: About 5,165 men completed a posttreatment survey after a median time of 18.6 months. A “bad” urinary incontinence score was reported by 9.3% of patients, and 4% also reported having had a big problem with their urinary function. Only 9.1% of patients with "bad" urinary incontinence scores underwent incontinence surgery within 6 months.

Study details: A retrospective study of 11,290 patients with prostate cancer who underwent radical prostatectomy between April 2014 and January 2016.

Disclosures: This work was supported by National Institute of Health Research, Medical Research Council, University College London Hospitals/University College London Comprehensive Biomedical Research Centre, and others. The authors received honoraria, advisory fees, travel expenses, and/or being employed outside this work.

Source: Parry MG et al. BJU Int. 2021 Nov 30. doi: 10.1111/bju.15663.

Key clinical point: Men with low-grade prostate cancer undergoing delayed radical prostatectomy (RP) after an initial period of active surveillance show a small increase in the use of secondary treatments, despite an increase in adverse pathology vs those undergoing immediate RP.

Major finding: The incidence of adverse pathology was higher with delayed vs immediate RP (49% vs 36%; P < .0001). Estimated 24‐month secondary treatment‐free probabilities in patients who received delayed and immediate RP were 93% and 96%, respectively (P = .0023).

Study details: A retrospective study of 1,878 patients with grade group 1 prostate cancer who underwent RP between April 2012 and July 2018.

Disclosures: This study is supported by the Blue Cross Blue Shield of Michigan Foundation. Some authors reported salary support. No other competing interests were disclosed.

Source: Arcot R et al. Prostate. 2021 Dec 2. doi: 10.1002/pros.24277.

Key clinical point: Men with low-grade prostate cancer undergoing delayed radical prostatectomy (RP) after an initial period of active surveillance show a small increase in the use of secondary treatments, despite an increase in adverse pathology vs those undergoing immediate RP.

Major finding: The incidence of adverse pathology was higher with delayed vs immediate RP (49% vs 36%; P < .0001). Estimated 24‐month secondary treatment‐free probabilities in patients who received delayed and immediate RP were 93% and 96%, respectively (P = .0023).

Study details: A retrospective study of 1,878 patients with grade group 1 prostate cancer who underwent RP between April 2012 and July 2018.

Disclosures: This study is supported by the Blue Cross Blue Shield of Michigan Foundation. Some authors reported salary support. No other competing interests were disclosed.

Source: Arcot R et al. Prostate. 2021 Dec 2. doi: 10.1002/pros.24277.

Key clinical point: Men with low-grade prostate cancer undergoing delayed radical prostatectomy (RP) after an initial period of active surveillance show a small increase in the use of secondary treatments, despite an increase in adverse pathology vs those undergoing immediate RP.

Major finding: The incidence of adverse pathology was higher with delayed vs immediate RP (49% vs 36%; P < .0001). Estimated 24‐month secondary treatment‐free probabilities in patients who received delayed and immediate RP were 93% and 96%, respectively (P = .0023).

Study details: A retrospective study of 1,878 patients with grade group 1 prostate cancer who underwent RP between April 2012 and July 2018.

Disclosures: This study is supported by the Blue Cross Blue Shield of Michigan Foundation. Some authors reported salary support. No other competing interests were disclosed.

Source: Arcot R et al. Prostate. 2021 Dec 2. doi: 10.1002/pros.24277.

Key clinical point: In patients with low-intermediate prostate cancer undergoing active surveillance, Gleason grade group (GG) 2 and positive targeted core are associated with significant risk for upgradation.

Major finding: At a median follow-up of 4.8 years, GG upgraded in 92 patients. GG2 (hazard ratio [HR], 2.93; 95% CI, 1.05-8.19) and 1 and more than 1 positive targeted cores (HR, 2.75; 95% CI, 1.25-6.03 and HR, 3.38; 95% CI, 1.65-6.91, respectively) at confirmatory magnetic resonance imaging (MRI)-guided biopsy were significant risk factor of upgradation.

Study details: A prospective study of 519 men with GG 1 and GG 2 prostate cancer undergoing active surveillance, who received confirmatory targeted and systemic MRI-guided biopsy followed by surveillance MRI-guided biopsy every 12 to 24 months.

Disclosures: This work was supported by National Cancer Institute, Center for Interventional Oncology, University of California, and others. Dr. L.S. Marks and Dr. A. Priester reported association with Avenda Health. No other competing interests were reported.

Source: Kinnaird A et al. J Urol. 2021 Dec 2. doi: 10.1097/JU.0000000000002343.

Key clinical point: In patients with low-intermediate prostate cancer undergoing active surveillance, Gleason grade group (GG) 2 and positive targeted core are associated with significant risk for upgradation.

Major finding: At a median follow-up of 4.8 years, GG upgraded in 92 patients. GG2 (hazard ratio [HR], 2.93; 95% CI, 1.05-8.19) and 1 and more than 1 positive targeted cores (HR, 2.75; 95% CI, 1.25-6.03 and HR, 3.38; 95% CI, 1.65-6.91, respectively) at confirmatory magnetic resonance imaging (MRI)-guided biopsy were significant risk factor of upgradation.

Study details: A prospective study of 519 men with GG 1 and GG 2 prostate cancer undergoing active surveillance, who received confirmatory targeted and systemic MRI-guided biopsy followed by surveillance MRI-guided biopsy every 12 to 24 months.

Disclosures: This work was supported by National Cancer Institute, Center for Interventional Oncology, University of California, and others. Dr. L.S. Marks and Dr. A. Priester reported association with Avenda Health. No other competing interests were reported.

Source: Kinnaird A et al. J Urol. 2021 Dec 2. doi: 10.1097/JU.0000000000002343.

Key clinical point: In patients with low-intermediate prostate cancer undergoing active surveillance, Gleason grade group (GG) 2 and positive targeted core are associated with significant risk for upgradation.

Major finding: At a median follow-up of 4.8 years, GG upgraded in 92 patients. GG2 (hazard ratio [HR], 2.93; 95% CI, 1.05-8.19) and 1 and more than 1 positive targeted cores (HR, 2.75; 95% CI, 1.25-6.03 and HR, 3.38; 95% CI, 1.65-6.91, respectively) at confirmatory magnetic resonance imaging (MRI)-guided biopsy were significant risk factor of upgradation.

Study details: A prospective study of 519 men with GG 1 and GG 2 prostate cancer undergoing active surveillance, who received confirmatory targeted and systemic MRI-guided biopsy followed by surveillance MRI-guided biopsy every 12 to 24 months.

Disclosures: This work was supported by National Cancer Institute, Center for Interventional Oncology, University of California, and others. Dr. L.S. Marks and Dr. A. Priester reported association with Avenda Health. No other competing interests were reported.

Source: Kinnaird A et al. J Urol. 2021 Dec 2. doi: 10.1097/JU.0000000000002343.

Key clinical point: Prostate-specific antigen (PSA)-based prostate cancer screening was associated with less overdiagnosis of low-risk cancer in statin users, with similar risk for advanced disease and mortality compared with nonusers.

Major finding: PSA screening was associated with increased prostate cancer incidence in statin nonusers (rate ratio [RR], 1.31; 95% CI, 1.24-1.38), but not in statin users (RR, 1.02; 95% CI, 0.95-1.10; P for interaction < .001). The screening was not associated with decreased mortality in statin users and nonusers.

Study details: A post hoc analysis of the Finnish Prostate Cancer Screening Trial in which 78,606 men were randomly assigned to either the screening or the control group.

Disclosures: This study was supported by Tampere University Hospital, Finnish Cancer Society, and Academy of Finland. The authors received grants, consulting/speaker/personal fees, research funding, compensation, and/or held patents outside this work.

Source: Vettenranta A et al. JAMA Oncol. 2021 Nov 24. doi: 10.1001/jamaoncol.2021.5672.

Key clinical point: Prostate-specific antigen (PSA)-based prostate cancer screening was associated with less overdiagnosis of low-risk cancer in statin users, with similar risk for advanced disease and mortality compared with nonusers.

Major finding: PSA screening was associated with increased prostate cancer incidence in statin nonusers (rate ratio [RR], 1.31; 95% CI, 1.24-1.38), but not in statin users (RR, 1.02; 95% CI, 0.95-1.10; P for interaction < .001). The screening was not associated with decreased mortality in statin users and nonusers.

Study details: A post hoc analysis of the Finnish Prostate Cancer Screening Trial in which 78,606 men were randomly assigned to either the screening or the control group.

Disclosures: This study was supported by Tampere University Hospital, Finnish Cancer Society, and Academy of Finland. The authors received grants, consulting/speaker/personal fees, research funding, compensation, and/or held patents outside this work.

Source: Vettenranta A et al. JAMA Oncol. 2021 Nov 24. doi: 10.1001/jamaoncol.2021.5672.

Key clinical point: Prostate-specific antigen (PSA)-based prostate cancer screening was associated with less overdiagnosis of low-risk cancer in statin users, with similar risk for advanced disease and mortality compared with nonusers.

Major finding: PSA screening was associated with increased prostate cancer incidence in statin nonusers (rate ratio [RR], 1.31; 95% CI, 1.24-1.38), but not in statin users (RR, 1.02; 95% CI, 0.95-1.10; P for interaction < .001). The screening was not associated with decreased mortality in statin users and nonusers.

Study details: A post hoc analysis of the Finnish Prostate Cancer Screening Trial in which 78,606 men were randomly assigned to either the screening or the control group.

Disclosures: This study was supported by Tampere University Hospital, Finnish Cancer Society, and Academy of Finland. The authors received grants, consulting/speaker/personal fees, research funding, compensation, and/or held patents outside this work.

Source: Vettenranta A et al. JAMA Oncol. 2021 Nov 24. doi: 10.1001/jamaoncol.2021.5672.